PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
 
PLoS One. 2016; 11(6): e0157306.
Published online 2016 June 9. doi:  10.1371/journal.pone.0157306
PMCID: PMC4900588

Amphipathic β2,2-Amino Acid Derivatives Suppress Infectivity and Disrupt the Intracellular Replication Cycle of Chlamydia pneumoniae

Massimiliano Galdiero, Editor

Abstract

We demonstrate in the current work that small cationic antimicrobial β2,2-amino acid derivatives (Mw < 500 Da) are highly potent against Chlamydia pneumoniae at clinical relevant concentrations (< 5 μM, i.e. < 3.4 μg/mL). C. pneumoniae is an atypical respiratory pathogen associated with frequent treatment failures and persistent infections. This gram-negative bacterium has a biphasic life cycle as infectious elementary bodies and proliferating reticulate bodies, and efficient treatment is challenging because of its long and obligate intracellular replication cycle within specialized inclusion vacuoles. Chlamydicidal effect of the β2,2-amino acid derivatives in infected human epithelial cells was confirmed by transmission electron microscopy. Images of infected host cells treated with our lead derivative A2 revealed affected chlamydial inclusion vacuoles 24 hours post infection. Only remnants of elementary and reticulate bodies were detected at later time points. Neither the EM studies nor resazurin-based cell viability assays showed toxic effects on uninfected host cells or cell organelles after A2 treatment. Besides the effects on early intracellular inclusion vacuoles, the ability of these β2,2-amino acid derivatives to suppress Chlamydia pneumoniae infectivity upon treatment of elementary bodies suggested also a direct interaction with bacterial membranes. Synthetic β2,2-amino acid derivatives that target C. pneumoniae represent promising lead molecules for development of antimicrobial agents against this hard-to-treat intracellular pathogen.

Introduction

Chlamydia pneumoniae (alternatively called Chlamydophila pneumoniae) is an air-borne respiratory tract pathogen typically causing a long-lasting dry cough with gradual onset [1, 2]. While approximately 70% of acute C. pneumoniae respiratory tract infections are mild or asymptomatic, a significant fraction of them cause more severe respiratory tract illnesses such as sinusitis, bronchitis and upper airway illnesses [3]. Furthermore, estimated 5–10% of community-acquired pneumonia cases are caused by C. pneumoniae, and especially the elderly patients often suffer from a severe illness upon encountering this pathogen [4].

In vitro susceptibility studies have shown that C. pneumoniae is sensitive to macrolides, tetracyclines and quinolones, but complete eradication of the infection is challenging. C. pneumoniae is resistant to sulfa drugs and trimethoprim, and treatment with penicillins can trigger the formation of a persistent state [5]. Treatment of C. pneumoniae infections is associated with relapsing symptoms and treatment failures even when the first-choice antibiotics are used. Up to 30% of patients with C. pneumoniae-caused community acquired pneumonia harbor the bacterium in a cultivable form even after the treatment and symptoms have ceased [5, 6]. Upon treatment failures and non-treated infections, the bacterium may convert to a chronic form characterized by morphological, transcriptional and metabolic changes different from the acute infectious phase. This persistent form of infection is ultimately refractory to even prolonged treatment with antibiotic agents [7, 8]. Despite its non-replicative nature, the persistent C. pneumoniae infection manipulates the host cell metabolism and signaling pathways, and activation of several proinflammatory and proliferative pathways are associated with the infection [9].

C. pneumoniae represents an atypical respiratory tract pathogen by being a gram-negative bacterium with an obligate intracellular replication cycle. Characteristic for the life cycle of C. pneumoniae are successive conversions between the extracellular, non-replicative but infectious elementary bodies (EBs), and the intracellular replicating reticulate bodies (RBs). Bacteria in the genus Chlamydia resemble other gram-negative bacteria as they have an outer membrane rich in negatively charged lipooligosaccharides (LOS) [10]. Recently, it has also been shown that Chlamydia spp. possess a peptidoglycan cell wall [11]. Cysteine-rich proteins are abundant in the proximity of the outer membrane of the Chlamydia cell envelope. These form extraordinary intra- and intermolecular disulfide cross-linkages involving proteins such as the major outer membrane protein (MOMP) and other periplasmic cysteine-rich proteins, which are suspected to play a crucial role in the structural rigidity and osmotic stability of the EBs form [12, 13]. Reduction of the disulfide bonds as well as opening of the supramolecular protein complexes occurs upon differentiation of the EBs to RBs shortly after entering the host cell and contributes to the fragile and osmolabile nature of the intracellular RB form [14]. Chlamydia spp. have developed means to support their intracellular survival. The formation of an inclusion vacuole, which is detached from the host cell’s endocytic vesicular system, is essential upon the bacterium’s entry into the host cell [15]. The inclusion membrane provides a protective niche by being an additional permeability barrier against cellular defense mechanisms and antimicrobial agents, and offers a surface for anchoring bacterial and host cell proteins favorable for the infection.

The negatively charged lipooligosaccharides embedded in the outer membrane of C. pneumoniae display a possible and favorable target structure for treatment with cationic antimicrobial peptides (AMPs). AMPs are a structurally diverse class of naturally existing anti-infective agents forming an essential component of the innate immune system of all multicellular organisms [16]. The antimicrobial activity of the majority of these peptides is tightly linked to their ability to electrostatically interact, insert and finally disrupt bacterial membranes. Selective interaction of AMPs with microbial membranes is explained by a higher negatively charged outer surface and lack of cholesterol compared to eukaryotic cell membranes. Similar observations have been made on cancer cells and several AMPs are regarded as promising cancer therapeutics, especially for treatment of resistant tumors [17, 18]. In order to have antimicrobial or anticancer properties, AMPs require in general a certain content and distribution of cationic and lipophilic residues enabling formation of amphipathic peptide conformations, rather than the presence of specific amino acid sequences [19].

The use of AMPs as potential pharmaceutical agents has been investigated during the last three decades. However, an inherent obstacle in using peptides as therapeutic agents is related to their unfavorable pharmacokinetic properties like compromised oral bioavailability, and low metabolic and proteolytic stability. Thus, most AMPs in clinical trials are developed as topical formulations [20]. A strategy to overcome these obstacles is to prepare peptidomimetics, which are molecules that maintain or improve essential peptide functionalities with respect to biological activity. These molecules are less susceptible to enzymatic degradation and have otherwise more favorable pharmacokinetic properties [21]. We have reported the synthesis of a series of peptide mimicking β2,2-amino acid derivatives that resemble small AMPs and additionally fulfill the physicochemical criteria set for orally bioavailable drugs [22]. These derivatives show activity against both gram-positive and gram-negative bacteria with minimum inhibitory concentration values between 4–8 μM while being basically nontoxic against human red blood cells. Of importance to the present study is the observation that β2,2-amino acid derivatives are able to permeate through artificial cell membranes by passive diffusion, and our hypothesis thereby became that they also could target intracellular residing pathogenic bacteria such as C. pneumoniae [22]. It has been reported that AMPs are able to effectively kill metabolically inactive extracellular EBs of C. pneumoniae and C. trachomatis [23]. However, bactericidal effects of AMPs on intracellular residing Chlamydia spp. is to our knowledge not reported.

In the current work, we demonstrate that derivatives A1 and A2, two out of our six studied β2,2-amino acid derivatives (Fig 1), are highly potent and able to inhibit Chlamydia pneumoniae infectivity and interfere with C. pneumoniae inclusions in human epithelial HL cells at concentrations below 5 μM (3.4 μg/mL). We hypothesize that the antichlamydial properties are based on a dual mechanism of action of these derivatives affecting both the EBs and early intracellular inclusions of C. pneumonia.

Fig 1
Structures of the investigated β2,2-amino acid derivatives A1—A6.

Materials and Methods

Derivatives A1—A6

The derivatives A1A6 were synthesized according to previous publications and isolated as di-trifluoroacetate salts [22, 24]. Purity was determined to > 95% with an analytical RP-HPLC C18-column and UV detection at 214 nm and 254 nm.

Cells and bacteria

Human epithelial HL cells [25] were grown in a RPMI1640 medium supplemented with 7.5% fetal bovine serum (FBS), 2 mM L-glutamine and 20 μg/ml gentamicin sulfate. A clinical C. pneumoniae isolate Kajaani 7 (K7), originally isolated from a young Finnish man suffering from pneumonia [26] was obtained from Professor Pekka Saikku (Department of Medicinal Microbiology, Institute of Diagnostics, University of Oulu, Finland) and a cardiovascular C. pneumoniae isolate CV-6 was obtained from Professor Matthias Maass (Paracelsus Medical University, Salzburg, Austria). The reference strains CWL-029 (VR-1310) and AR-39 (ATCC 53592) were obtained from American Type Culture Collection (ATCC). All strains were propagated in HL cells as previously described [27]. The K7 strain was used in all studies whereas CV-6 and the ATCC reference strains were used to confirm our initial compound screening data.

Infections

For all experiments applying immunofluorescence, HL cells were seeded in 24-well plates with coverslips at density of 4 x 105 cells/well and incubated overnight before infection. The cells were inoculated with C. pneumoniae at multiplicity of infection (MOI) 0.2 in the cell growth media supplemented with 1 μg/ml cycloheximide to enhance chlamydial growth [28]. The inoculated cultures were centrifuged at 550 g at 4°C for 1 h and incubated at 37°C for 1 h. Inocula were removed, fresh medium was added into wells and the plates were incubated for 70 h. Afterwards the cultures were fixed with methanol and the coverslips were stained with Pathfinder Chlamydia cell culture confirmation system (Bio-Rad) based on a genus-specific anti-LPS antibody to visualize the host cells and chlamydial inclusions. Detailed protocols for the infection and staining can be found in [29]. Unless otherwise stated in the text, the derivatives were added into the culture medium at 2 hours post infection (hpi), i.e., at the time when inocula were removed. Rifampicin (Fluka) at a concentration of 12 nM and azithromycin (Sigma) at a concentration 20 nM were used as a positive control in the infections, consistently yielding 95–98% inhibition in C. pneumoniae inclusion counts. DMSO concentration was adjusted to 0.1% in all experiments.

Delayed administration assay

HL cells were infected as described above and treated with derivatives at concentrations of 3 μM in order to cause inhibition of infection above 50%. The treatment of the infected cells was delayed by 4, 10 and 22 h and inclusions counts were subsequently performed as described above.

Infectious progeny assay

To measure the effects of the β2,2-amino acid derivatives on production of new infectious progeny by C. pneumoniae, HL cells were infected with C. pneumoniae as described above in the presence of the derivatives (at a concentration of 5 μM). At 72 hpi, medium was removed from the wells and 200 μl fresh medium was added. The cells were scraped off and then further lysed by vortexing with glass beads, and the lysates were used to infect fresh HL cell monolayers. Inclusion counts in the second passage of infection were determined with immunofluorescent staining as described above, and control wells fixed and stained after the first infectious cycle were used as internal controls.

Elementary body infectivity assay

C. pneumoniae EBs were suspended into the HL cell growth medium supplemented with cycloheximide at 400 000 inclusion forming units (IFU)/ml and exposed to 5 μM of the derivatives A1A6 for 1 h at 4°C. Immediately afterwards, aliquots of the EBs suspensions were used to infect HL cell monolayers as described above (MOI 0.2), resulting in typically 40–60 inclusions per eye field in nontreated control infections.

Transmission electron microscopy

HL cells were seeded in 6-well plates at 2 x 106 cells per well and cultured overnight. The cell monolayers were infected with C. pneumoniae (MOI 1) and treated with 2.5 μM of derivative A2 by adding it to the culture medium at 2 hpi based on findings in the dose-response assay. Untreated and uninfected HL control cells were incubated concurrently. The cells were pre-fixed at 24, 48 and 72 hpi with Karnovsky's fixative at 4°C, overnight. The samples were further processed for TEM as described in [30].

Cell viability assays

HL cells were seeded into 96-well plates at density 6 x 105 cells per well and incubated overnight before starting the exposure. The β2,2-amino acid derivatives were added at concentrations of 5 μM either in the presence or absence of 1 μg/ml cycloheximide in a final volume of 200 μl and the plates were incubated for 72 h. The resazurin assay was performed as described in Karlsson et al. [31].

Data analysis

All experiments were carried out as four replicates in minimum and the inclusion counts were determined as mean ± SEM of 4 eye fields per coverslip. For statistical analysis GraphPad Prism software v. 5.0 and Student’s t-test (p < 0.05) were applied.

Results

Inhibition of C. pneumoniae growth by β2,2-amino acid derivatives

Six β2,2-amino acid derivatives, comprising three different lipophilic side-chains and two different cationic C-termini (Fig 1) were assayed in a protocol in which human HL epithelial cell monolayers were infected with C. pneumoniae strain K7. At a concentration of 5 μM (A1, 3.4 μg/mL; A2, 3.2 μg/mL) the two derivatives, A1 and A2, yielded 95.6% and 100% reduction in inclusion counts with no substantial effect on host HL cell viability (Fig 2A). The derivatives A3 and A6 caused full inhibition of C. pneumoniae infectivity, however, we observed that host HL cells started to detach from the coverslips. The cell viability assay confirmed the rather cytotoxic properties of these two derivatives against HL cells and viability was determined to be 30.6% for A3 and 18.4% for A6. Derivative A4 showed 23.2% inhibition against C. pneumoniae and no cytotoxic effects against HL-cells whereas A5 caused 89.8% inhibition against C. pneumoniae and a 35.6% reduction of HL cell viability. As shown by the data from dose-response experiments, the anti-chlamydial effect of A1 and A2 was dose-dependent and IC50 values of 2 μM (A1, 1.4 μg/mL; A2, 1.3 μg/mL) were obtained for both compounds (Fig 2B). The antichlamydial efficacy of A1 and A2 was additionally confirmed using two ATCC reference strains, AR-39 and CWL-029, and a cardiovascular C. pneumoniae isolate CV-6. These strains showed similar susceptibility to treatment with 5 μM of these derivatives as observed for the K7 strain (data not shown).

Fig 2
Impact of β2,2-amino acid derivatives on C. pneumoniae inclusion counts and host cell viability.

Impact of administration time on C. pneumoniae inhibition

To further analyze the inhibitory properties of the two most promising β2,2-amino acid derivatives on C. pneumoniae growth, A1 and A2 were investigated in a delayed administration experiment. The addition of the derivatives into the culture medium of infected cell monolayers was postponed within the C. pneumoniae 72 h replication cycle. As indicated by the columns presented in Fig 3A, adding 3 μM of A1 into the culture medium according to the standard procedure (administration at 2 h, i.e. at the time of inocula removal) resulted in approximately 70% inhibition of inclusion vacuole counts, as expected. When A1 was added at 6 hpi or later, the inhibitory effect was significantly decreased to approximately 10–20% reduction in inclusion vacuole counts. Derivative A2 followed the same pattern with approximately 80% reduction of inclusion vacuole counts when added at 2 hpi, and showed only inhibiting effects on inclusion vacuole counts in a range between 20–30% when added at any later time points. The size of the remaining inclusion vacuoles did not differ from those in untreated control infections at any time point. Thus, the most pronounced effect caused by A1 and A2 on C. pneumoniae growth was exerted during the early stages of the infectious cycle.

Fig 3
Impact of delayed A1 and A2 administration and inhibition of infectious progeny production by the derivatives.

Impact on infectious progeny production

The ability of A1 and A2 to suppress the C. pneumoniae production of new infectious progeny was studied to gain more insight into the anti-chlamydial effects of these two derivatives. The results presented in Fig 3B show that inclusion vacuole counts detected in the second passage of infection were significantly lower in A1 and A2 treated infections than the inclusion vacuole counts of an untreated control infection. Consistent with the data obtained from the administration time experiments, neither A1 nor A2 suppressed C. pneumoniae infectious progeny production when they were administered into infected cell cultures at 6 hpi or later (data not shown).

Effects on C. pneumoniae elementary bodies

A hallmark of AMPs and AMP derived compounds is their ability to act on metabolically quiescent bacteria by a membrane disruptive mechanism of action. We studied the impact of the β2,2-amino acid derivatives on the metabolically quiescent infectious EBs of C. pneumoniae that are able to resist both harsh environmental factors and treatment with antibiotics [32]. Infectious EB suspensions were treated with each of the derivatives A1—A6 at 5 μM for 1 h prior to inoculation on HL cell monolayers in order to gain insight into susceptibility of the EB membranes to all derivatives. As shown in Fig 4, all six derivatives decreased C. pneumoniae EB infectivity, with A3 and A6 being the most potent derivatives in this respect, causing 77% and 90% inhibition. Treatment of EBs with A4 and A5 resulted in 20% and 66% reduction of infectivity. The two derivatives A1 and A2, capable of suppressing C. pneumoniae inclusion counts in the context of cellular infections (see above) caused up to 50% decrease in infectivity upon EB pretreatment, indicating that these compounds, too, were able to target C. pneumoniae EB membranes. No HL cell detachment or morphological changes were observed during these experiments, indicating that the fractions of compounds to which HL cells were exposed in these conditions did not cause cytotoxic effects.

Fig 4
Treatment of C. pneumoniae elementary bodies with derivatives A1—A6.

Transmission electron microscopy (TEM)

TEM was used to trace intracellular changes upon C. pneumoniae infection and treatment with the lead derivative A2 (Fig 5). Treatment of HL cells with 2.5 μM of A2 over a time-span of 72 hpi did not result in remarkable changes in cell or organelle morphology compared with uninfected and untreated control cells (Fig 5Ia, 5lb, 5IIa and 5IIb). After infection with EBs and subsequent incubation for 24 h, RBs were visible in untreated control cells (Fig 5IIIa and 5IIIb) whereas affected inclusion vacuoles were visible in cells treated with A2 (Fig 5IVa and 5IVb). By extending the incubation time to 48 h we observed an increased number of RBs per inclusion vacuole and expansion of the latter (Fig 5Va and 5Vb). Treatment with A2 resulted in smaller inclusions, which only contained fragments of RBs and EBs (Fig 5VIa and 5VIb). After a 72 hpi course of the study, extended accumulations of RBs, redifferentiating RBs, and spherical EBs were visible in the untreated HL-cells (Fig 5VIIa and 5VIIb). Miniature bodies characteristic for C. pneumoniae were also visible. In contrast, no RBs or EBs were present in the A2 treated cells, but inclusion vacuoles containing remnants of RBs and EBs after C. pneumoniae infection were visible (Fig 5VIIIa and 5VIIIb).

Fig 5
Transmission electron microscopy images of HL-cells.

Discussion

Despite some recent advances in diagnostics and basic biological studies, C. pneumoniae remains a challenging target for pharmacological intervention as illustrated by the high ratio of treatment failures with currently available antibiotics [6]. In contrast to most other respiratory pathogens, no resistant mutants of C. pneumoniae have been isolated from clinical samples to date. Even strains originating from patients with treatment failure do not show altered in vitro susceptibility profiles to antibiotics. Furthermore, previous in vitro studies do not show remarkable differences in antibiotic susceptibility between different C. pneumoniae reference strains or clinical isolates [3335]. These observations indicate that persistence, rather than resistance, is responsible for the treatment challenges and emphasizes the need for novel types of antichlamydial agents not relying on bacterial replication.

In our earlier studies, various β2,2-amino acid derivatives have been shown to be active against multi-resistant bacteria and to be able to permeate through phospholipid membranes [22]. Furthermore, we have reported that biofilms formed by Staphylococcus aureus and Escherichia coli are susceptible to treatment with these β2,2-amino acid derivatives [36]. We have also demonstrated that some have anticancer activity by either attacking mitochondria in cancer cells or the cancer cell membrane and that this is related to differences in molecular structure [30]. The antimicrobial and permeability properties of β2,2-amino acid derivatives encouraged us to investigate if the intracellular pathogen C. pneumoniae is susceptible to these AMP derived compounds. Therefore, infected human epithelial HL cells as well as C. pneumoniae EBs were used in the screening.

A direct interaction of β2,2-amino acid derivatives with negatively charged heparan-sulfate and LOS containing bacterial membranes of EBs during the initial phase of infection can, to a certain extent, explain the anti-chlamydial effect of the derivatives. A3 and A6 were the most potent derivatives when applied to EBs prior to infection. Previous studies have shown that these two derivatives display pronounced membranolytic properties compared to other related β2,2-amino acid derivatives [24]. In contrast, A1 and A2 were non-toxic and both derivatives decreased C. pneumoniae infectivity when the bacterial EBs were treated prior to infection. Thus, interactions of A1 and A2 with C. pneumoniae EBs during the late attachment phase to HL cells (~ 2 hpi, onset of incubation) appear plausible. As a consequence, cell entry and development of infection was hampered.

Compared to other types of nonconventional anti-chlamydial compounds previously identified by us, such as flavonoids and betulin-derived compounds [27, 37, 38], the present β2,2-amino acid derivatives show similar or higher potencies against C. pneumoniae. Of note, the ability of flavonoles like quercetin, rhamnetin and morin to penetrate membranes seems crucial for their anti-chlamydial properties [27]. We thus hypothesize that the anti-chlamydial properties of A1 and A2 are also based on their ability to passively diffuse across the HL cell phospholipid bilayer and a subsequently form electrostatic interactions with C. pneumoniae bacterial and/or cellular inclusion membranes inside the infected HL-cells. We suspect that negative charges are present on endocytic vesicles containing C. pneumoniae EBs as reported for the inclusion vacuoles of a related pathogen Chlamydia trachomatis [39]. The negative charges on the endocytic vesicle originate from the membrane lipid phosphatidylserine, which is preferentially found on the inner leaflet of cell membranes. However, during endocytosis topological inversion of the phospholipid bilayer occurs and phosphatidylserine is located on the endosome exterior, as illustrated in Fig 6. According to the proposed mechanisms of actions for AMPs, the following event is interaction of the lipophilic side chains of the amphipathic β2,2-amino acid derivatives with the inclusion vacuole membrane and, upon disintegration, elimination of this protective niche needed for C. pneumoniae replication. We further hypothesize that the inclusion vacuole membrane and physiological processes connected to it are more susceptible to derivate interaction than the inner leaflet of the cell membrane, which is supported by our viability data.

Fig 6
Schematic drawing of HL cell infection by C. pneumoniae and potential intervention points of β2,2-amino acid derivatives.

The proposed mechanism of action is further supported by data acquired during the delayed administration assay. Time experiments showed that postponing the administration of A1 or A2 by only four hours (from 2 to 6 h) reduced drastically the anti-chlamydial effect (Fig 3A). This indicated that these derivatives suppress C. pneumoniae growth by affecting the events occurring in the early stages of the bacterial replication cycle. Similar observations have been made for the 21 amino acid long cell penetrating peptide Pep-1 and the 69 residue long intracellular expressed AMP CIT 1a [40, 41]. Both peptides were screened against C. trachomatis and displayed their highest activity during the initial stages of infection. The hours following the entry of Chlamydia into host cells are known to involve various remodeling processes of cellular membranes or organelles induced by the bacterium, as reviewed in Ronzone et al. [15]. The endocytic vesicle in which the EB is internalized is turned into an inclusion vacuole by incorporation of a unique combination of bacterial and host cell membrane proteins. Exocytic vesicles, multivesicular bodies and lipid droplets are trafficked into the inclusion vacuole to provide lipids as energy source and building blocks for the bacterium. Moreover, Chlamydia induced pathways prevent the fusion of the bacterium-endosomes with acidifying membrane organelles, which provides a neutral pH in the inclusion vacuole and protects the bacterium from degradation pathways [42].

Yeung et al. have reported that the related bacterium C. trachomatis actively manipulates the composition of endosome membrane charge and phospholipid composition [39]. While the abundance of phosphatidylserine in the outer leaflet of endosomal vesicles normally triggers the fusion of the vesicle with lysosomes, C. trachomatis is able to reorganize the vesicle by reducing the phosphatidylserine content and overall negative charge of the membrane’s outer leaflet. These changes were found to occur by 6 h post infection, which coincides with the observation from the delayed administration experiment of the current study (lack of inhibition when A1 or A2 were administered at 6 h or later). Of note, the β2,2-amino acid derivatives possess a considerably lower amount of positive charges (+2) compared to the intracellular expressed probes (+5) used by Yeung et al. [39]. This charge difference might be a possible explanation for the considerable drop in activity of A1 and A2 after 6 h. Thus, the impact of cationic charge on anti-chlamydial potency of future derivatives must be thoroughly evaluated since increasing the net positive charge might as well adversely affect the membrane penetrating properties of the β2,2-amino acid derivatives. These data further suggest a dual mechanism of action involving both destabilization of EBs and inclusion membranes. The results also indicate that A1 and A2 are active before C. pneumoniae enters its replication cycle, but further studies are needed to fully elucidate the detailed anti-chlamydial mechanism of action of these β2,2-amino acid derivatives.

Conclusion

To our knowledge, the current work represents the first report on AMP-like compounds with activity against intracellular bacteria. The investigated β2,2-amino acid derivatives are chlamydicidal in nature and inhibit C. pneumoniae at clinical relevant concentrations. Thus, by exhibiting improved pharmacokinetic properties compared to many reported AMPs the β2,2-amino acid derivatives A1 and A2 demonstrate an important principle and are promising lead molecules for further drug development of agents with inhibitory activity against the intracellular pathogen C. pneumoniae.

Acknowledgments

The authors thank Ingeborg Smeds for excellent technical assistance and the staff at the Electron Microscopy Department, UiT – The Arctic University of Norway, for preparation of ultra-sections and technical advice.

Funding Statement

Academy of Finland (grant 252216 to LH and 272266 to PMV) and Tor, Joe och Pentti Borgs minnesfond are acknowledged for the financial support. The project was further supported by the transition grant of the Faculty of Health Sciences, UiT-The Arctic University of Norway (DA) and the Research Council of Norway, “Fellesløftet”, Grant-214493/F20 (MBS). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Data Availability

Data Availability

All relevant data are presented within the paper.

References

1. Hahn DL, Azenabor AA, Beatty WL, Byrne GI. Chlamydia pneumoniae as a respiratory pathogen. Front Biosci. 2002;7: E66–E76. [PubMed]
2. Blasi F, Tarsia P, Aliberti S. Chlamydophila pneumoniae. Clin Microbiol Infect. 2009;15: 29–35. [PubMed]
3. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis. 2007;44: 568–576. [PubMed]
4. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103: 309–316. doi: 10.1016/j.rmed.2008.08.006 [PubMed]
5. Hanski L, Vuorela PM. Recent advances in technologies for developing drugs against Chlamydia pneumoniae. Expert Opin Drug Discovery. 2014;9: 791–802. [PubMed]
6. Kohlhoff SA, Hammerschlag MR. Treatment of chlamydial infections: 2014 update. Expert Opin Pharmacother. 2015;16: 205–212. doi: 10.1517/14656566.2015.999041 [PubMed]
7. Beatty WL, Morrison RP, Byrne GI. Persistent chlamydiae: From cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev. 1994;58: 686–699. [PMC free article] [PubMed]
8. Skilton RJ, Cutcliffen LT, Barlow D, Wang Y, Salim O, Lambden PR, et al. Penicillin-induced persistence in Chlamydia trachomatis: High quality time lapse video analysis of the developmental cycle. PLoS One. 2009;4: e7723 doi: 10.1371/journal.pone.0007723 [PMC free article] [PubMed]
9. Kern JM, Maass V, Maass M. Chlamydia pneumoniae -induced pathological signaling in the vasculature. FEMS Immunol Med Microbiol. 2009;55: 131–139. doi: 10.1111/j.1574-695X.2008.00514.x [PubMed]
10. Nguyen BD, Cunningham D, Liang X, Chen X, Toone EJ, Raetz CRH, et al. Lipooligosaccharide is required for the generation of infectious elementary bodies in Chlamydia trachomatis. Proc. Natl. Acad. Sci. U.S.A. 2011;108: 10284–10289. doi: 10.1073/pnas.1107478108 [PubMed]
11. Liechti GW, Kuru E, Hall E, Kalinda A, Brun YV, VanNieuwenhze M, et al. A new metabolic cell-wall labelling method reveals peptidoglycan in Chlamydia trachomatis. Nature. 2014;506: 507–510. doi: 10.1038/nature12892 [PMC free article] [PubMed]
12. Bavoil P, Ohlin A, Schachter J. Role of disulfide bonding in outer membrane structure and permeability in Chlamydia trachomatis. Infect Immun. 1984;44: 479–485. [PMC free article] [PubMed]
13. Hatch TP. Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in Chlamydiae? J Bacteriol. 1996;178: 1–5. [PMC free article] [PubMed]
14. Hatch TP, Miceli M, Sublett JE. Synthesis of disulfide-bonded outer membrane proteins during the developmental cycle of Chlamydia psittaci and Chlamydia trachomatis. J Bacteriol. 1986;165: 379–385. [PMC free article] [PubMed]
15. Ronzone E, Wesolowski J, Paumet F. Manipulation of host vesicular trafficking and membrane fusion during Chlamydia infection. In: Mares M, editor. Chlamydia: Intech; 2012. p. 45–74.
16. Pasupuleti M, Schmidtchen A, Malmsten M. Antimicrobial peptides: key components of the innate immune system. Crit Rev Biotechnol. 2012;32: 143–171. doi: 10.3109/07388551.2011.594423 [PubMed]
17. Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta, Biomembr. 2008;1778: 357–375. [PMC free article] [PubMed]
18. Chu H-L, Yip B-S, Chen K-H, Yu H-Y, Chih Y-H, Cheng H-T, et al. Novel antimicrobial peptides with high anticancer activity and selectivity. PLoS One. 2015;10: e0126390 doi: 10.1371/journal.pone.0126390 [PMC free article] [PubMed]
19. Yin LM, Edwards MA, Li J, Yip CM, Deber CM. Roles of Hydrophobicity and Charge Distribution of Cationic Antimicrobial Peptides in Peptide-Membrane Interactions. J Biol Chem. 2012;287: 7738–7745. doi: 10.1074/jbc.M111.303602 [PMC free article] [PubMed]
20. Afacan NJ, Yeung ATY, Pena OM, Hancock REW. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Des. 2012;18: 807–819. [PubMed]
21. Rotem S, Mor A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim Biophys Acta, Biomembr. 2009;1788: 1582–1592. [PubMed]
22. Hansen T, Ausbacher D, Flaten GE, Havelkova M, Strøm MB. Synthesis of cationic antimicrobial β2,2-amino acid derivatives with potential for oral administration. J Med Chem. 2011;54: 858–868. doi: 10.1021/jm101327d [PubMed]
23. Donati M, Di Leo K, Benincasa M, Cavrini F, Accardo S, Moroni A, et al. Activity of cathelicidin peptides against Chlamydia spp. Antimicrob Agents Chemother. 2005;49: 1201–1202. [PMC free article] [PubMed]
24. Hansen T, Ausbacher D, Zachariassen ZG, Anderssen T, Havelkova M, Strøm MB. Anticancer activity of small amphipathic β2,2-amino acid derivatives. Eur J Med Chem. 2012;58: 22–29. doi: 10.1016/j.ejmech.2012.09.048 [PubMed]
25. Kuo CC, Grayston JT. A sensitive cell line, HL cells, for isolation and propagation of Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990;162: 755–758. [PubMed]
26. Ekman MR, Grayston JT, Visakorpi R, Kleemola M, Kuo CC, Saikku P. An epidemic of infections due to Chlamydia pneumoniae in military conscripts. Clin Infect Dis. 1993;17: 420–425. [PubMed]
27. Alvesalo J, Vuorela H, Tammela P, Leinonen M, Saikku P, Vuorela P. Inhibitory effect of dietary phenolic compounds on Chlamydia pneumoniae in cell cultures. Biochem Pharmacol. 2006;71: 735–741. [PubMed]
28. Kuo C-C. Chlamydia pneumoniae: Culture Methods In: Allegra L, Blasi F, editors. Chlamydia pneumoniae: The Lung and the Heart. Milano: Springer Milan; 1999. pp. 9–15.
29. Hanski L, Genina N, Uvell H, Malinovskaja K, Gylfe A, Laaksonen T, et al. Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation. PLoS One. 2014;9: e115115 doi: 10.1371/journal.pone.0115115 [PMC free article] [PubMed]
30. Ausbacher D, Svineng G, Hansen T, Strøm MB. Anticancer mechanisms of action of two small amphipathic β2,2-amino acid derivatives derived from antimicrobial peptides. Biochim Biophys Acta, Biomembr. 2012;1818: 2917–2925. [PubMed]
31. Karlsson D, Fallarero A, Brunhofer G, Mayer C, Prakash O, Mohan CG, et al. The exploration of thienothiazines as selective butyrylcholinesterase inhibitors. Eur J Pharm Sci. 2012;47: 190–205. doi: 10.1016/j.ejps.2012.05.014 [PubMed]
32. Siewert K, Rupp J, Klinger M, Solbach W, Gieffers J. Growth cycle-dependent pharmacodynamics of antichlamydial drugs. Antimicrobial Agents and Chemotherapy. 2005;49: 1852–1856. [PMC free article] [PubMed]
33. Chotikanatis K, Kohlhoff SA, Hammerschlag MR. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy. 2014;58: 1800–1801. doi: 10.1128/AAC.02263-13 [PMC free article] [PubMed]
34. Kohlhoff SA, Huband MD, Hammerschlag MR. In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy. 2014;58: 7595–7596. doi: 10.1128/AAC.03920-14 [PMC free article] [PubMed]
35. Roblin PM, Kohlhoff SA, Parker C, Hammerschlag MR. In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae. Antimicrobial Agents and Chemotherapy. 2010;54: 1358–1359. doi: 10.1128/AAC.01343-09 [PMC free article] [PubMed]
36. Ausbacher D, Fallarero A, Kujala J, Määttänen A, Peltonen J, Strøm MB, et al. Staphylococcus aureus biofilm susceptibility to small and potent β2,2-amino acid derivatives. Biofouling. 2014;30: 81–93. doi: 10.1080/08927014.2013.847924 [PubMed]
37. Salin O, Alakurtti S, Pohjala L, Siiskonen A, Maass V, Maass M, et al. Inhibitory effect of the natural product betulin and its derivatives against the intracellular bacterium Chlamydia pneumoniae Biochem Pharmacol. 2010;80: 1141–1151. doi: 10.1016/j.bcp.2010.06.051 [PubMed]
38. Salin O, Tormakangas L, Leinonen M, Saario E, Hagstrom M, Ketola RA, et al. Corn Mint (Mentha arvensis) Extract Diminishes Acute Chlamydia pneumoniae Infection in vitro and in vivo. JAgricFood Chem. 2011;59: 12836–12842. [PubMed]
39. Yeung T, Heit B, Dubuisson JF, Fairn GD, Chiu B, Inman R, et al. Contribution of phosphatidylserine to membrane surface charge and protein targeting during phagosome maturation. J Cell Biol. 2009;185: 917–928. doi: 10.1083/jcb.200903020 [PMC free article] [PubMed]
40. Lazarev VN, Shkarupeta MM, Polina NF, Kostrjukova ES, Vassilevski AA, Kozlov SA, et al. Antimicrobial peptide from spider venom inhibits Chlamydia trachomatis infection at an early stage. Arch Microbiol. 2013;195: 173–179. doi: 10.1007/s00203-012-0863-5 [PubMed]
41. Park N, Yamanaka K, Tran D, Chandrangsu P, Akers JC, de Leon JC, et al. The cell-penetrating peptide, Pep-1, has activity against intracellular chlamydial growth but not extracellular forms of Chlamydia trachomatis J Antimicrob Chemother. 2009;63: 115–123. doi: 10.1093/jac/dkn436 [PMC free article] [PubMed]
42. Al-Younes HM, Rudel T, Meyer TF. Characterization and intracellular trafficking pattern of vacuoles containing Chlamydia pneumoniae in human epithelial cells. Cell Microbiol. 1999;1: 237–247. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science